- Home
- MDCX vs ANEB Comparison
MDCX vs ANEB Comparison
Compare MDCX & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | ANEB |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 96.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDCX | ANEB |
|---|---|---|
| Price | $1.69 | $2.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 349.6K | 21.7K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.59 | $0.80 |
| 52 Week High | $8.94 | $3.42 |
Technical Indicators
Market Signals| Indicator | MDCX | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 37.41 | 41.98 |
| Support Level | $1.68 | $1.91 |
| Resistance Level | $2.03 | $2.40 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 14.93 | 51.77 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.